<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37253553</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000884</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2022-000884</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Treat-to-target (T2T) strategies are advocated to improve prognosis in childhood-onset SLE (cSLE). Proposed T2T states include SLEDAI score of <u>&lt;</u>4 (SLEDAI-LD), limited corticosteroid use (low-CS), and lupus low disease activity state (LLDAS). We sought to compare T2T states for their association with cSLE prognosis under consideration of relevant disease characteristics such as pre-existing damage, race and lupus nephritis (LN).</AbstractText><AbstractText Label="METHODS">Longitudinal data from 165 patients enrolled in the Cincinnati Lupus Registry were included. LN presence was based on renal biopsy, and patients were followed up until 18 years of age.</AbstractText><AbstractText Label="RESULTS">The 165 patients (LN: 45, white: 95) entered the registry within a median of 0 (IQR: 0-1) year post diagnosis and were followed up for a median of 4 (IQR: 2-5) years during which 80%, 92% and 94% achieved LLDAS, low-CS and SLEDAI-LD. Patients with LN were significantly less likely to achieve any T2T state (all p<u>&lt;</u>0.03) and required a significantly longer time to reach them (all p&lt;0.0001). Over the study period, patients maintained low-CS, SLEDAI-LD or LLDAS for a median of 76% (IQR: 48%-100%), 86% (IQR: 55%-100%) or 39% (IQR: 13%-64%) of their follow-up. Significant predictors of failure to maintain LLDAS included LN (p&#x2264;0.0062), pre-existing damage (p&#x2264;0.0271) and non-white race (p&#x2264;0.0013). There were 22%, 20% and 13% of patients who reached SLEDAI-LD, CS-low and LLDAS and nonetheless acquired new damage. Patients with LN had a higher risk of new damage than patients without LN even if achieving low-CS (p=0.009) or LLDAS (p=0.04).</AbstractText><AbstractText Label="CONCLUSIONS">Patients with LN and pre-existing damage are at higher risk of increased future damage acquisition, even if achieving a T2T state such as LLDAS. Among proposed common T2T states, the LLDAS is the hardest to achieve and maintain. The LLDAS may be considered the preferred T2T measure as it conveys the highest protection from acquiring additional disease damage.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cody</LastName><ForeName>Ellen M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Pediatrics, Division of Nephrology, Hypertension and Pheresis, Washington University in St Louis, St Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Bridget E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Pediatrics, Cincinnati Children's Hospital Medical Center Burnet Campus, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogbu</LastName><ForeName>Ekemini A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center Burnet Campus, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pediatrics, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huggins</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center Burnet Campus, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pediatrics, Division of Epidemiology &amp; Biostatistics, Cincinnati Children's Hospital Medical Center Burnet Campus, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Pediatrics, Division of Epidemiology &amp; Biostatistics, Cincinnati Children's Hospital Medical Center Burnet Campus, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ting</LastName><ForeName>Tracy V</ForeName><Initials>TV</Initials><AffiliationInfo><Affiliation>Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center Burnet Campus, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Pediatrics, Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center Burnet Campus, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Pediatrics, Division of Epidemiology &amp; Biostatistics, Cincinnati Children's Hospital Medical Center Burnet Campus, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunner</LastName><ForeName>Hermine I</ForeName><Initials>HI</Initials><Identifier Source="ORCID">0000-0001-9478-2987</Identifier><AffiliationInfo><Affiliation>Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center Burnet Campus, Cincinnati, Ohio, USA hermine.brunner@cchmc.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AR076316</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AR070549</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Glucocorticoids</Keyword><Keyword MajorTopicYN="N">Lupus Erythematosus, Systemic</Keyword><Keyword MajorTopicYN="N">Lupus Nephritis</Keyword><Keyword MajorTopicYN="N">Outcome Assessment, Health Care</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>31</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>30</Day><Hour>20</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37253553</ArticleId><ArticleId IdType="pmc">PMC10230998</ArticleId><ArticleId IdType="doi">10.1136/lupus-2022-000884</ArticleId><ArticleId IdType="pii">10/1/e000884</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2018;32:188&#x2013;205. 10.1016/j.berh.2018.09.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2018.09.004</ArticleId><ArticleId IdType="pubmed">30527426</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva CA, Avcin T, Brunner HI. Taxonomy for systemic lupus erythematosus with onset before adulthood. Arthritis Care Res (Hoboken) 2012;64:1787&#x2013;93. 10.1002/acr.21757</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.21757</ArticleId><ArticleId IdType="pmc">PMC3463746</ArticleId><ArticleId IdType="pubmed">22730317</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EMD, Lythgoe H, Midgley A, et al. . Juvenile-onset systemic lupus erythematosus: update on clinical presentation, pathophysiology and treatment options. Clinical Immunology 2019;209:108274. 10.1016/j.clim.2019.108274</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2019.108274</ArticleId><ArticleId IdType="pubmed">31678365</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgia RE, Silverman ED. Childhood-onset systemic lupus erythematosus: an update. Curr Opin Rheumatol 2015;27:483&#x2013;92. 10.1097/BOR.0000000000000208</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000208</ArticleId><ArticleId IdType="pubmed">26200474</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven RF, Mosca M, Bertsias G, et al. . Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73:958&#x2013;67. 10.1136/annrheumdis-2013-205139</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205139</ArticleId><ArticleId IdType="pubmed">24739325</ArticleId></ArticleIdList></Reference><Reference><Citation>Groot N, de Graeff N, Avcin T, et al. . European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis 2017;76:1788&#x2013;96. 10.1136/annrheumdis-2016-210960</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-210960</ArticleId><ArticleId IdType="pubmed">28630236</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollander MC, Sage JM, Greenler AJ, et al. . International consensus for provisions of quality-driven care in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2013;65:1416&#x2013;23. 10.1002/acr.21998</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.21998</ArticleId><ArticleId IdType="pubmed">23463586</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EMD, Tharmaratnam K, Al-Abadi E, et al. . Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus. Rheumatology (Oxford) 2022;61:3378&#x2013;89. 10.1093/rheumatology/keab915</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab915</ArticleId><ArticleId IdType="pmc">PMC9348762</ArticleId><ArticleId IdType="pubmed">34894234</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner HI, Silverman ED, To T, et al. . Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 2002;46:436&#x2013;44. 10.1002/art.10072</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10072</ArticleId><ArticleId IdType="pubmed">11840446</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J, Chalhoub NE, Sherwin CM, et al. . Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum 2019;49:251&#x2013;9. 10.1016/j.semarthrit.2019.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2019.03.010</ArticleId><ArticleId IdType="pmc">PMC6744986</ArticleId><ArticleId IdType="pubmed">30987856</ArticleId></ArticleIdList></Reference><Reference><Citation>Thamer M, Hern&#xe1;n MA, Zhang Y, et al. . Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009;36:560&#x2013;4. 10.3899/jrheum.080828</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.080828</ArticleId><ArticleId IdType="pmc">PMC3624968</ArticleId><ArticleId IdType="pubmed">19208608</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba&#xf1;ez D, Gladman DD, Urowitz MB. Adjusted mean systemic lupus erythematosus disease activity Index-2K is a Predictor of outcome in SLE. J Rheumatol 2005;32:824&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15868616</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford) 2020;59:v69&#x2013;81. 10.1093/rheumatology/keaa403</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa403</ArticleId><ArticleId IdType="pmc">PMC7719039</ArticleId><ArticleId IdType="pubmed">33280011</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklyn K, Lau CS, Navarra SV, et al. . Definition and initial validation of a lupus low disease activity State (LLDAS). Ann Rheum Dis 2016;75:1615&#x2013;21. 10.1136/annrheumdis-2015-207726</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207726</ArticleId><ArticleId IdType="pubmed">26458737</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Mendoza-Pinto C, Re&#xe1;tegui-Sokolova C, et al. . Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review. Lupus Sci Med 2021;8:e000542. 10.1136/lupus-2021-000542</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000542</ArticleId><ArticleId IdType="pmc">PMC8458331</ArticleId><ArticleId IdType="pubmed">34548375</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma C, Raymond W, Eilertsen G, et al. . Association of achieving lupus low disease activity state fifty percent of the time with both reduced damage accrual and mortality in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2020;72:447&#x2013;51. 10.1002/acr.23867</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23867</ArticleId><ArticleId IdType="pubmed">30821926</ArticleId></ArticleIdList></Reference><Reference><Citation>Piga M, Floris A, Cappellazzo G, et al. . Failure to achieve lupus low disease activity State (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. Arthritis Res Ther 2017;19:247. 10.1186/s13075-017-1451-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1451-5</ArticleId><ArticleId IdType="pmc">PMC5681839</ArticleId><ArticleId IdType="pubmed">29126432</ArticleId></ArticleIdList></Reference><Reference><Citation>Babaoglu H, Li J, Goldman D, et al. . Predictors of predominant lupus low disease activity State (LLDAS-50). Lupus 2019;28:1648&#x2013;55. 10.1177/0961203319886028</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319886028</ArticleId><ArticleId IdType="pmc">PMC6872940</ArticleId><ArticleId IdType="pubmed">31694446</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozturk K, Caglayan S, Tanatar A, et al. . Low disease activity state in juvenile-onset systemic lupus erythematosus. Lupus 2021;30:2144&#x2013;50. 10.1177/09612033211054399</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211054399</ArticleId><ArticleId IdType="pubmed">34723709</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahadat MJ, van den Berg L, Timmermans D, et al. . LLDAS is an attainable treat-to-target goal in childhood-onset SLE. Lupus Sci Med 2021;8:e000571. 10.1136/lupus-2021-000571</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000571</ArticleId><ArticleId IdType="pmc">PMC8719245</ArticleId><ArticleId IdType="pubmed">34969874</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner HI, Bennett MR, Gulati G, et al. . Urine biomarkers to predict response to lupus nephritis therapy in children and young adults. J Rheumatol 2017;44:1239&#x2013;48. 10.3899/jrheum.161128</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.161128</ArticleId><ArticleId IdType="pmc">PMC6719540</ArticleId><ArticleId IdType="pubmed">28620062</ArticleId></ArticleIdList></Reference><Reference><Citation>Mina R, Harris JG, Klein-Gitelman MS, et al. . Initial Benchmarking of the quality of medical care in Childhood&#x2010;Onset systemic lupus erythematosus. Arthritis Care &amp; Research 2016;68:179&#x2013;86. 10.1002/acr.22666</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22666</ArticleId><ArticleId IdType="pmc">PMC4720574</ArticleId><ArticleId IdType="pubmed">26219749</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725. 10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SR, Brinks R, Costenbader KH, et al. . Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and Ethnicities. Ann Rheum Dis 2020;79:1333&#x2013;9. 10.1136/annrheumdis-2020-217162</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217162</ArticleId><ArticleId IdType="pubmed">32816709</ArticleId></ArticleIdList></Reference><Reference><Citation>Aljaberi N, Nguyen K, Strahle C, et al. . Performance of the new 2019 European League against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus in children and young adults. Arthritis Care Res (Hoboken) 2021;73:580&#x2013;5. 10.1002/acr.24430</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24430</ArticleId><ArticleId IdType="pubmed">32841547</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner HI, Feldman BM, Bombardier C, et al. . Sensitivity of the systemic lupus erythematosus disease activity index, British Isles lupus assessment group index, and systemic lupus activity measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum 1999;42:1354&#x2013;60. 10.1002/1529-0131(199907)42:7&lt;1354::AID-ANR8&gt;3.0.CO;2-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(199907)42:7&lt;1354::AID-ANR8&gt;3.0.CO;2-4</ArticleId><ArticleId IdType="pubmed">10403262</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D, Ginzler E, Goldsmith C, et al. . The development and initial validation of the systemic lupus International collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363&#x2013;9. 10.1002/art.1780390303</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780390303</ArticleId><ArticleId IdType="pubmed">8607884</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Medicare &amp; Medicaid Services . International classification of diseases. 2022. Available: https://www.cms.gov/Medicare/Coding/ICD10</Citation></Reference><Reference><Citation>Harris PA, Taylor R, Thielke R, et al. . Research electronic data capture (Redcap)--A Metadata-driven methodology and Workflow process for providing Translational research Informatics support. J Biomed Inform 2009;42:377&#x2013;81. 10.1016/j.jbi.2008.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2008.08.010</ArticleId><ArticleId IdType="pmc">PMC2700030</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Mina R, Harris JG, Klein-Gitelman MS, et al. . Initial Benchmarking of the quality of medical care in childhood-onset systemic lupus erythematosus. Arthritis Care &amp; Research 2016;68:179&#x2013;86. 10.1002/acr.22666</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22666</ArticleId><ArticleId IdType="pmc">PMC4720574</ArticleId><ArticleId IdType="pubmed">26219749</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Goldsmith CH, Urowitz MB, et al. . The systemic lupus International collaborating clinics/American college of rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus International comparison. J Rheumatol 2000;27:373&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10685799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce IN, O&#x2019;Keeffe AG, Farewell V, et al. . Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus International collaborating clinics (SLICC) inception cohort. Ann Rheum Dis 2015;74:1706&#x2013;13. 10.1136/annrheumdis-2013-205171</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205171</ArticleId><ArticleId IdType="pmc">PMC4552899</ArticleId><ArticleId IdType="pubmed">24834926</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland MJ, Beresford MW, Feldman BM, et al. . Measuring disease damage and its severity in Childhood&#x2010;Onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2018;70:1621&#x2013;9. 10.1002/acr.23531</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23531</ArticleId><ArticleId IdType="pubmed">29409150</ArticleId></ArticleIdList></Reference><Reference><Citation>Mina R, Klein-Gitelman MS, Nelson S, et al. . Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus. Ann Rheum Dis 2014;73:401&#x2013;6. 10.1136/annrheumdis-2012-202376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202376</ArticleId><ArticleId IdType="pubmed">23345596</ArticleId></ArticleIdList></Reference><Reference><Citation>Mina R, Abulaban K, Klein-Gitelman MS, et al. . Validation of the lupus nephritis clinical indices in childhood-onset systemic lupus erythematosus. Arthritis Care &amp; Research 2016;68:195&#x2013;202. 10.1002/acr.22651</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22651</ArticleId><ArticleId IdType="pmc">PMC4720587</ArticleId><ArticleId IdType="pubmed">26213987</ArticleId></ArticleIdList></Reference><Reference><Citation>Groot N, de Graeff N, Marks SD, et al. . European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis 2017;76:1965&#x2013;73. 10.1136/annrheumdis-2017-211898</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211898</ArticleId><ArticleId IdType="pubmed">28877866</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisaoglu H, Baba O, Kalyoncu M. Lupus low disease activity state as a treatment target for pediatric patients with lupus nephritis. Pediatr Nephrol 2023;38:1167&#x2013;75. 10.1007/s00467-022-05742-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-022-05742-8</ArticleId><ArticleId IdType="pubmed">36156735</ArticleId></ArticleIdList></Reference><Reference><Citation>Floris A, Piga M, Perra D, et al. . Treatment target in newly diagnosed systemic lupus erythematosus: the Association of lupus low disease activity state and remission with lower accrual of early damage. Arthritis Care Res (Hoboken) 2020;72:1794&#x2013;9. 10.1002/acr.24086</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24086</ArticleId><ArticleId IdType="pubmed">31600023</ArticleId></ArticleIdList></Reference><Reference><Citation>Moral Larraz A, Cuenca Carcel&#xe9;n S, Aparicio L&#xf3;pez C, et al. . Lupus nephritis in children. Andes Pediatr 2021;92:420&#x2013;7. 10.32641/rchped.v92i3.2960</Citation><ArticleIdList><ArticleId IdType="doi">10.32641/rchped.v92i3.2960</ArticleId><ArticleId IdType="pubmed">34479249</ArticleId></ArticleIdList></Reference><Reference><Citation>Golder V, Kandane-Rathnayake R, Hoi AY-B, et al. . Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. Arthritis Res Ther 2016;18:260. 10.1186/s13075-016-1163-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-016-1163-2</ArticleId><ArticleId IdType="pmc">PMC5103412</ArticleId><ArticleId IdType="pubmed">27829463</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin B, Lightstone L. Renoprotective strategies in lupus nephritis: beyond immunosuppression. Lupus 2013;22:1267&#x2013;73. 10.1177/0961203313505927</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313505927</ArticleId><ArticleId IdType="pubmed">24097999</ArticleId></ArticleIdList></Reference><Reference><Citation>Bargman JM, Avila-Casado C. Resolution of proteinuria in lupus nephritis: hurry up and wait. J Rheumatol 2014;41:622&#x2013;5. 10.3899/jrheum.140157</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.140157</ArticleId><ArticleId IdType="pubmed">24692601</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Smith J, Brunner HI. Update on the treatment and outcome of systemic lupus erythematous in children. Curr Opin Rheumatol 2019;31:464&#x2013;70. 10.1097/BOR.0000000000000621</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000621</ArticleId><ArticleId IdType="pubmed">31107290</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>